ID   CRTC2_HUMAN             Reviewed;         693 AA.
AC   Q53ET0; Q6UUV8; Q7Z3X7; Q8N332;
DT   05-FEB-2008, integrated into UniProtKB/Swiss-Prot.
DT   05-FEB-2008, sequence version 2.
DT   07-APR-2021, entry version 130.
DE   RecName: Full=CREB-regulated transcription coactivator 2;
DE   AltName: Full=Transducer of regulated cAMP response element-binding protein 2;
DE            Short=TORC-2;
DE            Short=Transducer of CREB protein 2;
GN   Name=CRTC2; Synonyms=TORC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT CYS-379, AND FUNCTION.
RX   PubMed=14506290; DOI=10.1073/pnas.1932773100;
RA   Iourgenko V., Zhang W., Mickanin C., Daly I., Jiang C., Hexham J.M.,
RA   Orth A.P., Miraglia L., Meltzer J., Garza D., Chirn G.-W., McWhinnie E.,
RA   Cohen D., Skelton J., Terry R., Yu Y., Bodian D., Buxton F.P., Zhu J.,
RA   Song C., Labow M.A.;
RT   "Identification of a family of cAMP response element-binding protein
RT   coactivators by genome-scale functional analysis in mammalian cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12147-12152(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   TISSUE=Brain;
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=PNS, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=14536081; DOI=10.1016/j.molcel.2003.08.013;
RA   Conkright M.D., Canettieri G., Screaton R., Guzman E., Miraglia L.,
RA   Hogenesch J.B., Montminy M.;
RT   "TORCs: transducers of regulated CREB activity.";
RL   Mol. Cell 12:413-423(2003).
RN   [6]
RP   INTERACTION WITH CREB1; SIK2; PPP3CA; YWHAB AND YWHAG, TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, FUNCTION, PHOSPHORYLATION AT SER-70; SER-90; SER-136;
RP   SER-171; SER-306; SER-368; SER-393; SER-433; SER-456; SER-489; SER-492 AND
RP   SER-613, IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF SER-171
RP   AND SER-368.
RX   PubMed=15454081; DOI=10.1016/j.cell.2004.09.015;
RA   Screaton R.A., Conkright M.D., Katoh Y., Best J.L., Canettieri G.,
RA   Jeffries S., Guzman E., Niessen S., Yates J.R. III, Takemori H.,
RA   Okamoto M., Montminy M.;
RT   "The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive
RT   coincidence detector.";
RL   Cell 119:61-74(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=15589160; DOI=10.1016/j.cub.2004.11.002;
RA   Bittinger M.A., McWhinnie E., Meltzer J., Iourgenko V., Latario B., Liu X.,
RA   Chen C.H., Song C., Garza D., Labow M.;
RT   "Activation of cAMP response element-mediated gene expression by regulated
RT   nuclear transport of TORC proteins.";
RL   Curr. Biol. 14:2156-2161(2004).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-171, AND MUTAGENESIS
RP   OF SER-171.
RX   PubMed=16817901; DOI=10.1111/j.1742-4658.2006.05291.x;
RA   Katoh Y., Takemori H., Lin X.-Z., Tamura M., Muraoka M., Satoh T.,
RA   Tsuchiya Y., Min L., Doi J., Miyauchi A., Witters L.A., Nakamura H.,
RA   Okamoto M.;
RT   "Silencing the constitutive active transcription factor CREB by the LKB1-
RT   SIK signaling cascade.";
RL   FEBS J. 273:2730-2748(2006).
RN   [9]
RP   INTERACTION WITH HTLV-1 TAX (MICROBIAL INFECTION), AND FUNCTION.
RX   PubMed=16809310; DOI=10.1128/jvi.00103-06;
RA   Siu Y.-T., Chin K.-T., Siu K.-L., Yee Wai Choy E., Jeang K.-T., Jin D.-Y.;
RT   "TORC1 and TORC2 coactivators are required for tax activation of the human
RT   T-cell leukemia virus type 1 long terminal repeats.";
RL   J. Virol. 80:7052-7059(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-433, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [11]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16980408; DOI=10.1073/pnas.0606714103;
RA   Wu Z., Huang X., Feng Y., Handschin C., Feng Y., Gullicksen P.S., Bare O.,
RA   Labow M., Spiegelman B., Stevenson S.C.;
RT   "Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha
RT   transcription and mitochondrial biogenesis in muscle cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:14379-14384(2006).
RN   [12]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-171.
RX   PubMed=17210223; DOI=10.1016/j.mce.2006.12.020;
RA   Takemori H., Kanematsu M., Kajimura J., Hatano O., Katoh Y., Lin X.-Z.,
RA   Min L., Yamazaki T., Doi J., Okamoto M.;
RT   "Dephosphorylation of TORC initiates expression of the StAR gene.";
RL   Mol. Cell. Endocrinol. 265:196-204(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-433, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION AT SER-171 AND SER-274, INTERACTION WITH 14-3-3, AND
RP   MUTAGENESIS OF SER-171; SER-274 AND SER-368.
RX   PubMed=18626018; DOI=10.1073/pnas.0800796105;
RA   Jansson D., Ng A.C., Fu A., Depatie C., Al Azzabi M., Screaton R.A.;
RT   "Glucose controls CREB activity in islet cells via regulated
RT   phosphorylation of TORC2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10161-10166(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-86; SER-90; SER-136;
RP   SER-433; THR-501; SER-613 AND SER-624, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-86; SER-90; THR-192;
RP   SER-433; TYR-488; SER-490; SER-613 AND SER-624, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-501; SER-613 AND SER-624, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-433; SER-613 AND SER-624, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90 AND SER-613, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-234, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [25]
RP   INTERACTION WITH YWHAE AND PPP3CA.
RX   PubMed=30611118; DOI=10.1016/j.isci.2018.12.012;
RA   Sonntag T., Ostojic J., Vaughan J.M., Moresco J.J., Yoon Y.S.,
RA   Yates J.R. III, Montminy M.;
RT   "Mitogenic Signals Stimulate the CREB Coactivator CRTC3 through PP2A
RT   Recruitment.";
RL   IScience 11:134-145(2018).
RN   [26]
RP   VARIANT CYS-379, AND INVOLVEMENT IN SUSCEPTIBILITY TO NIDDM.
RX   PubMed=17950019; DOI=10.1016/j.ymgme.2007.08.125;
RA   Keshavarz P., Inoue H., Nakamura N., Yoshikawa T., Tanahashi T.,
RA   Itakura M.;
RT   "Single nucleotide polymorphisms in genes encoding LKB1 (STK11), TORC2
RT   (CRTC2) and AMPK alpha2-subunit (PRKAA2) and risk of type 2 diabetes.";
RL   Mol. Genet. Metab. 93:200-209(2008).
CC   -!- FUNCTION: Transcriptional coactivator for CREB1 which activates
CC       transcription through both consensus and variant cAMP response element
CC       (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway,
CC       being active when dephosphorylated and acts independently of CREB1
CC       'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4.
CC       Regulates gluconeogenesis as a component of the LKB1/AMPK/TORC2
CC       signaling pathway. Regulates the expression of specific genes such as
CC       the steroidogenic gene, StAR. Potent coactivator of PPARGC1A and
CC       inducer of mitochondrial biogenesis in muscle cells. Also coactivator
CC       for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1)
CC       long terminal repeats (LTR). {ECO:0000269|PubMed:14506290,
CC       ECO:0000269|PubMed:14536081, ECO:0000269|PubMed:15454081,
CC       ECO:0000269|PubMed:16809310, ECO:0000269|PubMed:16817901,
CC       ECO:0000269|PubMed:16980408, ECO:0000269|PubMed:17210223}.
CC   -!- SUBUNIT: Binds, as a tetramer, through its N-terminal region, with the
CC       bZIP domain of CREB1 (PubMed:15454081). 'Arg-314' in the bZIP domain of
CC       CREB1 is essential for this interaction (PubMed:15454081). Interaction,
CC       via its C-terminal, with TAF4, enhances recruitment of TAF4 to CREB1
CC       (PubMed:15454081). Interacts with SIK2 (PubMed:15454081). Interacts
CC       with 14-3-3 proteins, YWHAB and YWHAG (PubMed:15454081,
CC       PubMed:18626018). Interacts (probably when phosphorylated at Ser-171)
CC       with YWHAE (PubMed:30611118). Interacts with calmodulin-dependent
CC       catalytic subunit PPP3CA/calcineurin A (PubMed:15454081,
CC       PubMed:30611118). Interaction with COP1 mediates nuclear export and
CC       degradation of CRTC2 (By similarity). {ECO:0000250|UniProtKB:Q3U182,
CC       ECO:0000269|PubMed:15454081, ECO:0000269|PubMed:18626018,
CC       ECO:0000269|PubMed:30611118}.
CC   -!- SUBUNIT: (Microbial infection) Interaction with the human T-cell
CC       leukemia virus type 1 (HTLV-1) Tax protein is essential for optimal
CC       transcription activation by Tax. {ECO:0000269|PubMed:16809310}.
CC   -!- INTERACTION:
CC       Q53ET0; P18850: ATF6; NbExp=3; IntAct=EBI-1181987, EBI-852157;
CC       Q53ET0; Q8N5M1: ATPAF2; NbExp=3; IntAct=EBI-1181987, EBI-1166928;
CC       Q53ET0; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-1181987, EBI-10961624;
CC       Q53ET0; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-1181987, EBI-396137;
CC       Q53ET0; P16220: CREB1; NbExp=3; IntAct=EBI-1181987, EBI-711855;
CC       Q53ET0; Q15233: NONO; NbExp=2; IntAct=EBI-1181987, EBI-350527;
CC       Q53ET0; Q9UMX1: SUFU; NbExp=5; IntAct=EBI-1181987, EBI-740595;
CC       Q53ET0; P03206: BZLF1; Xeno; NbExp=3; IntAct=EBI-1181987, EBI-2621186;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15589160}. Nucleus
CC       {ECO:0000269|PubMed:15589160}. Note=Translocated from the nucleus to
CC       the cytoplasm on interaction of the phosphorylated form with 14-3-3
CC       protein (PubMed:15454081). In response to cAMP levels and glucagon,
CC       relocated to the nucleus (PubMed:15454081).
CC       {ECO:0000269|PubMed:15454081}.
CC   -!- TISSUE SPECIFICITY: Most abundantly expressed in the thymus. Present in
CC       both B and T-lymphocytes. Highly expressed in HEK293T cells and in
CC       insulinomas. High levels also in spleen, ovary, muscle and lung, with
CC       highest levels in muscle. Lower levels found in brain, colon, heart,
CC       kidney, prostate, small intestine and stomach. Weak expression in liver
CC       and pancreas. {ECO:0000269|PubMed:14536081,
CC       ECO:0000269|PubMed:15454081, ECO:0000269|PubMed:16980408}.
CC   -!- PTM: Phosphorylation/dephosphorylation states of Ser-171 are required
CC       for regulating transduction of CREB activity (PubMed:15589160,
CC       PubMed:17210223). CRTCs/TORCs are inactive when phosphorylated, and
CC       active when dephosphorylated at this site (PubMed:17210223). This
CC       primary site of phosphorylation, is regulated by cAMP and calcium
CC       levels and is dependent on the phosphorylation of SIKs (SIK1 and SIK2)
CC       by LKB1 (PubMed:15454081, PubMed:16817901). Following adenylyl cyclase
CC       activation, dephosphorylated at Ser-171 by PPP3CA/calcineurin A
CC       resulting in CRTC2 dissociation from 14-3-3 proteins and PPP3CA (By
CC       similarity). Both insulin and AMPK increase this phosphorylation of
CC       CRTC2 while glucagon suppresses it (PubMed:15454081). Phosphorylation
CC       at Ser-274 by MARK2 is induced under low glucose conditions and
CC       dephosphorylated in response to glucose influx (PubMed:18626018).
CC       Phosphorylation at Ser-274 promotes interaction with 14-3-3 proteins
CC       and translocation to the cytoplasm (PubMed:18626018).
CC       {ECO:0000250|UniProtKB:Q3U182, ECO:0000269|PubMed:15454081,
CC       ECO:0000269|PubMed:15589160, ECO:0000269|PubMed:16817901,
CC       ECO:0000269|PubMed:17210223, ECO:0000269|PubMed:18626018}.
CC   -!- PTM: Asymmetric dimethylation of arginine resisues by PRMT6 enhances
CC       the association of CRTC2 with CREB on the promoters of gluconeogenic
CC       genes. {ECO:0000250|UniProtKB:Q3U182}.
CC   -!- POLYMORPHISM: Variant Cys-379, under a dominant model, linked to a
CC       recessive mutation in LKB1, may be associated with susceptibility to
CC       type II or non-insulin-dependent diabetes mellitus (NIDDM).
CC       {ECO:0000269|PubMed:17950019}.
CC   -!- SIMILARITY: Belongs to the TORC family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CRTC2ID50581ch1q21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY360172; AAQ98857.1; -; mRNA.
DR   EMBL; AK223559; BAD97279.1; -; mRNA.
DR   EMBL; AL358472; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC028886; AAH28886.1; -; mRNA.
DR   EMBL; BC053562; AAH53562.1; -; mRNA.
DR   CCDS; CCDS30875.1; -.
DR   RefSeq; NP_859066.1; NM_181715.2.
DR   PDB; 4HTM; X-ray; 2.00 A; A=18-50.
DR   PDBsum; 4HTM; -.
DR   SMR; Q53ET0; -.
DR   BioGRID; 128308; 49.
DR   DIP; DIP-29950N; -.
DR   IntAct; Q53ET0; 28.
DR   MINT; Q53ET0; -.
DR   STRING; 9606.ENSP00000357622; -.
DR   GlyGen; Q53ET0; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q53ET0; -.
DR   PhosphoSitePlus; Q53ET0; -.
DR   BioMuta; CRTC2; -.
DR   DMDM; 167009135; -.
DR   EPD; Q53ET0; -.
DR   jPOST; Q53ET0; -.
DR   MassIVE; Q53ET0; -.
DR   MaxQB; Q53ET0; -.
DR   PaxDb; Q53ET0; -.
DR   PeptideAtlas; Q53ET0; -.
DR   PRIDE; Q53ET0; -.
DR   ProteomicsDB; 62448; -.
DR   Antibodypedia; 34141; 546 antibodies.
DR   Ensembl; ENST00000368633; ENSP00000357622; ENSG00000160741.
DR   GeneID; 200186; -.
DR   KEGG; hsa:200186; -.
DR   UCSC; uc057leo.1; human.
DR   CTD; 200186; -.
DR   DisGeNET; 200186; -.
DR   GeneCards; CRTC2; -.
DR   HGNC; HGNC:27301; CRTC2.
DR   HPA; ENSG00000160741; Low tissue specificity.
DR   MIM; 608972; gene.
DR   neXtProt; NX_Q53ET0; -.
DR   OpenTargets; ENSG00000160741; -.
DR   PharmGKB; PA142672073; -.
DR   VEuPathDB; HostDB:ENSG00000160741.16; -.
DR   eggNOG; ENOG502QVWA; Eukaryota.
DR   GeneTree; ENSGT00390000010652; -.
DR   InParanoid; Q53ET0; -.
DR   OMA; RHIIDSS; -.
DR   OrthoDB; 1118500at2759; -.
DR   PhylomeDB; Q53ET0; -.
DR   TreeFam; TF321571; -.
DR   PathwayCommons; Q53ET0; -.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SIGNOR; Q53ET0; -.
DR   BioGRID-ORCS; 200186; 26 hits in 1001 CRISPR screens.
DR   ChiTaRS; CRTC2; human.
DR   GeneWiki; CRTC2; -.
DR   GenomeRNAi; 200186; -.
DR   Pharos; Q53ET0; Tbio.
DR   PRO; PR:Q53ET0; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q53ET0; protein.
DR   Bgee; ENSG00000160741; Expressed in small intestine Peyer's patch and 185 other tissues.
DR   ExpressionAtlas; Q53ET0; baseline and differential.
DR   Genevisible; Q53ET0; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0008140; F:cAMP response element binding protein binding; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0006094; P:gluconeogenesis; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0043970; P:histone H3-K9 acetylation; IEA:Ensembl.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0051289; P:protein homotetramerization; IEA:InterPro.
DR   GO; GO:1901998; P:toxin transport; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR024786; TORC.
DR   InterPro; IPR024785; TORC_C.
DR   InterPro; IPR024784; TORC_M.
DR   InterPro; IPR024783; TORC_N.
DR   PANTHER; PTHR13589; PTHR13589; 1.
DR   Pfam; PF12886; TORC_C; 1.
DR   Pfam; PF12885; TORC_M; 1.
DR   Pfam; PF12884; TORC_N; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Cytoplasm; Host-virus interaction;
KW   Isopeptide bond; Methylation; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..693
FT                   /note="CREB-regulated transcription coactivator 2"
FT                   /id="PRO_0000318528"
FT   MOTIF           271..287
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        236..240
FT                   /note="Poly-Ser"
FT   COMPBIAS        336..408
FT                   /note="Ser-rich"
FT   SITE            629
FT                   /note="Required for ubiquitination and degradation"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         51
FT                   /note="Asymmetric dimethylarginine; by PRMT6"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U182"
FT   MOD_RES         70
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332"
FT   MOD_RES         86
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         90
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         99
FT                   /note="Asymmetric dimethylarginine; by PRMT6"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U182"
FT   MOD_RES         120
FT                   /note="Asymmetric dimethylarginine; by PRMT6"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U182"
FT   MOD_RES         123
FT                   /note="Asymmetric dimethylarginine; by PRMT6"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U182"
FT   MOD_RES         136
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         161
FT                   /note="Asymmetric dimethylarginine; by PRMT6"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U182"
FT   MOD_RES         168
FT                   /note="Asymmetric dimethylarginine; by PRMT6"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U182"
FT   MOD_RES         169
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U182"
FT   MOD_RES         171
FT                   /note="Phosphoserine; by AMPK, MARK2, SIK1 and SIK2"
FT                   /evidence="ECO:0000269|PubMed:15454081,
FT                   ECO:0000269|PubMed:16817901, ECO:0000269|PubMed:17210223,
FT                   ECO:0000269|PubMed:18626018"
FT   MOD_RES         192
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         274
FT                   /note="Phosphoserine; by MARK2"
FT                   /evidence="ECO:0000269|PubMed:18626018"
FT   MOD_RES         306
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081"
FT   MOD_RES         393
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081"
FT   MOD_RES         433
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081,
FT                   ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         456
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081"
FT   MOD_RES         488
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         489
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081"
FT   MOD_RES         490
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         492
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081"
FT   MOD_RES         501
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15454081,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         623
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U182"
FT   MOD_RES         624
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        234
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         147
FT                   /note="M -> V (in dbSNP:rs11264680)"
FT                   /id="VAR_038756"
FT   VARIANT         379
FT                   /note="R -> C (in dbSNP:rs150423770)"
FT                   /evidence="ECO:0000269|PubMed:14506290,
FT                   ECO:0000269|PubMed:17950019"
FT                   /id="VAR_038757"
FT   MUTAGEN         70
FT                   /note="S->A: No effect on cAMP- and calcium-regulated
FT                   phosphorylation."
FT   MUTAGEN         171
FT                   /note="S->A: Loss of cAMP- and calcium-regulated
FT                   phosphorylation. Greatly reduced interaction with 14-3-3
FT                   proteins. Impaired phosphorylation under low glucose
FT                   conditions and impaired interaction with 14-3-3 proteins;
FT                   when associated with A-274."
FT                   /evidence="ECO:0000269|PubMed:15454081,
FT                   ECO:0000269|PubMed:16817901, ECO:0000269|PubMed:18626018"
FT   MUTAGEN         274
FT                   /note="S->A: Impaired phosphorylation under low glucose
FT                   conditions and impaired interaction with 14-3-3 proteins;
FT                   when associated with A-171."
FT                   /evidence="ECO:0000269|PubMed:18626018"
FT   MUTAGEN         368
FT                   /note="S->A: Reduced cAMP- and calcium-regulated
FT                   phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:15454081,
FT                   ECO:0000269|PubMed:18626018"
FT   MUTAGEN         393
FT                   /note="S->A: No effect on cAMP- and calcium-regulated
FT                   phosphorylation."
FT   CONFLICT        323..325
FT                   /note="MGL -> HGP (in Ref. 1; AAQ98857)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        499
FT                   /note="P -> S (in Ref. 2; BAD97279)"
FT                   /evidence="ECO:0000305"
FT   HELIX           21..45
FT                   /evidence="ECO:0007744|PDB:4HTM"
SQ   SEQUENCE   693 AA;  73302 MW;  EE6C52E0ECDC1DF1 CRC64;
     MATSGANGPG SATASASNPR KFSEKIALQK QRQAEETAAF EEVMMDIGST RLQAQKLRLA
     YTRSSHYGGS LPNVNQIGSG LAEFQSPLHS PLDSSRSTRH HGLVERVQRD PRRMVSPLRR
     YTRHIDSSPY SPAYLSPPPE SSWRRTMAWG NFPAEKGQLF RLPSALNRTS SDSALHTSVM
     NPSPQDTYPG PTPPSILPSR RGGILDGEMD PKVPAIEENL LDDKHLLKPW DAKKLSSSSS
     RPRSCEVPGI NIFPSPDQPA NVPVLPPAMN TGGSLPDLTN LHFPPPLPTP LDPEETAYPS
     LSGGNSTSNL THTMTHLGIS RGMGLGPGYD APGLHSPLSH PSLQSSLSNP NLQASLSSPQ
     PQLQGSHSHP SLPASSLARH VLPTTSLGHP SLSAPALSSS SSSSSTSSPV LGAPSYPAST
     PGASPHHRRV PLSPLSLLAG PADARRSQQQ LPKQFSPTMS PTLSSITQGV PLDTSKLSTD
     QRLPPYPYSS PSLVLPTQPH TPKSLQQPGL PSQSCSVQSS GGQPPGRQSH YGTPYPPGPS
     GHGQQSYHRP MSDFNLGNLE QFSMESPSAS LVLDPPGFSE GPGFLGGEGP MGGPQDPHTF
     NHQNLTHCSR HGSGPNIILT GDSSPGFSKE IAAALAGVPG FEVSAAGLEL GLGLEDELRM
     EPLGLEGLNM LSDPCALLPD PAVEESFRSD RLQ
//
